StockNews.com upgraded shares of Exelixis (NASDAQ:EXEL – Get Rating) from a hold rating to a buy rating in a research report report published on Friday morning. A number of other equities research analysts also recently issued reports on the stock. Morgan Stanley reduced their price objective on shares of Exelixis from $22.00 to $21.00 and […]
Exelixis, Inc. (NASDAQ:EXEL – Get Rating) was the target of unusually large options trading on Tuesday. Stock investors purchased 2,454 call options on the stock. This is an increase of 111% compared to the typical daily volume of 1,163 call options. Analyst Upgrades and Downgrades A number of equities analysts recently commented on EXEL shares. […]
Meritage Portfolio Management lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 164.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 424,235 shares of the biotechnology company’s stock after purchasing an additional 264,052 shares during the quarter. Meritage Portfolio Management’s […]
Meritage Portfolio Management raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Get Rating) by 164.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 424,235 shares of the biotechnology company’s stock after buying an additional 264,052 shares during the quarter. Meritage Portfolio […]
A number of research firms have changed their ratings and price targets for Exelixis (NASDAQ: EXEL): 4/14/2023 – Exelixis was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating. 4/12/2023 – Exelixis had its price target lowered by analysts at Morgan Stanley from $22.00 to $21.00. They now have an “equal […]